Cargando…

The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study

Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Algahtani, Fahad Dhafer, Elabbasy, Mohamed Tharwat, Samak, Mai A., Adeboye, Adeniyi A., Yusuf, Rafeek A., Ghoniem, Mohamed E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401801/
https://www.ncbi.nlm.nih.gov/pubmed/34441048
http://dx.doi.org/10.3390/medicina57080842
_version_ 1783745637257314304
author Algahtani, Fahad Dhafer
Elabbasy, Mohamed Tharwat
Samak, Mai A.
Adeboye, Adeniyi A.
Yusuf, Rafeek A.
Ghoniem, Mohamed E.
author_facet Algahtani, Fahad Dhafer
Elabbasy, Mohamed Tharwat
Samak, Mai A.
Adeboye, Adeniyi A.
Yusuf, Rafeek A.
Ghoniem, Mohamed E.
author_sort Algahtani, Fahad Dhafer
collection PubMed
description Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required.
format Online
Article
Text
id pubmed-8401801
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84018012021-08-29 The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study Algahtani, Fahad Dhafer Elabbasy, Mohamed Tharwat Samak, Mai A. Adeboye, Adeniyi A. Yusuf, Rafeek A. Ghoniem, Mohamed E. Medicina (Kaunas) Article Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required. MDPI 2021-08-19 /pmc/articles/PMC8401801/ /pubmed/34441048 http://dx.doi.org/10.3390/medicina57080842 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Algahtani, Fahad Dhafer
Elabbasy, Mohamed Tharwat
Samak, Mai A.
Adeboye, Adeniyi A.
Yusuf, Rafeek A.
Ghoniem, Mohamed E.
The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
title The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
title_full The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
title_fullStr The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
title_full_unstemmed The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
title_short The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
title_sort prospect of lactoferrin use as adjunctive agent in management of sars-cov-2 patients: a randomized pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401801/
https://www.ncbi.nlm.nih.gov/pubmed/34441048
http://dx.doi.org/10.3390/medicina57080842
work_keys_str_mv AT algahtanifahaddhafer theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT elabbasymohamedtharwat theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT samakmaia theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT adeboyeadeniyia theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT yusufrafeeka theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT ghoniemmohamede theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT algahtanifahaddhafer prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT elabbasymohamedtharwat prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT samakmaia prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT adeboyeadeniyia prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT yusufrafeeka prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy
AT ghoniemmohamede prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy